Endocannabinoids control spasticity in a multiple sclerosis model.

Journal article

Spasticity is a complicating sign in multiple sclerosis that also develops in a model of chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice. In areas associated with nerve damage, increased levels of the endocannabinoids, anandamide (arachidonoylethanolamide, AEA) and 2-arachidonoyl glycerol (2-AG), and of the AEA congener, palmitoylethanolamide (PEA), were detected here, whereas comparable levels of these compounds were found in normal and non-spastic CREAE mice. Whi...

Expand abstract

Authors: Baker, D; Pryce, G; Croxford, J; Brown, P; Pertwee, R

• Publication status: Published
• Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology
• Volume: 15
• Issue: 2
• Pages: 300-302
• Publication date: 2001-02-01
• DOI: 10.1096/fj.00-0399fje
• EISSN: 1530-6860
• ISSN: 0892-6638
• Language: English
• Keywords: Disease Models, Animal; Cannabinoids; Spasm; Humans; Mice; Encephalomyelitis, Autoimmune, Experimental; Receptors, Cannabinoid; Endocannabinoids; Piperidines; Animals; Glycerides; Pyrazoles; Arachidonic Acids; Multiple Sclerosis; Polyunsaturated Alkamides; Mice, Inbred Strains; Spinal Cord; Brain; Receptors, Drug; Palmitic Acids